MX2022015229A - Mejora de la tolerabilidad de anticuerpos asociada con la administracion intravenosa. - Google Patents

Mejora de la tolerabilidad de anticuerpos asociada con la administracion intravenosa.

Info

Publication number
MX2022015229A
MX2022015229A MX2022015229A MX2022015229A MX2022015229A MX 2022015229 A MX2022015229 A MX 2022015229A MX 2022015229 A MX2022015229 A MX 2022015229A MX 2022015229 A MX2022015229 A MX 2022015229A MX 2022015229 A MX2022015229 A MX 2022015229A
Authority
MX
Mexico
Prior art keywords
administration
antibody
intravenous
mice
isolation
Prior art date
Application number
MX2022015229A
Other languages
English (en)
Spanish (es)
Inventor
Ingrid Teige
Linda Mårtensson
Björn Frendéus
Ingrid Karlsson
Original Assignee
Bioinvent Int Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP20178287.7A external-priority patent/EP3919077A1/en
Application filed by Bioinvent Int Ab filed Critical Bioinvent Int Ab
Publication of MX2022015229A publication Critical patent/MX2022015229A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A61K49/0008—Screening agents using (non-human) animal models or transgenic animal models or chimeric hosts, e.g. Alzheimer disease animal model, transgenic model for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • C07K14/721—Steroid/thyroid hormone superfamily, e.g. GR, EcR, androgen receptor, oestrogen receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Pathology (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
MX2022015229A 2020-06-04 2021-06-04 Mejora de la tolerabilidad de anticuerpos asociada con la administracion intravenosa. MX2022015229A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP20178287.7A EP3919077A1 (en) 2020-06-04 2020-06-04 Model for prediction of tolerability issues in connection with intravenous administration of therapeutic antibodies
EP21163703 2021-03-19
PCT/EP2021/065014 WO2021245238A1 (en) 2020-06-04 2021-06-04 Improving antibody tolerability associated with intravenous administration

Publications (1)

Publication Number Publication Date
MX2022015229A true MX2022015229A (es) 2023-02-09

Family

ID=76217874

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022015229A MX2022015229A (es) 2020-06-04 2021-06-04 Mejora de la tolerabilidad de anticuerpos asociada con la administracion intravenosa.

Country Status (12)

Country Link
US (2) US20230322933A1 (cg-RX-API-DMAC10.html)
EP (2) EP4161574A1 (cg-RX-API-DMAC10.html)
JP (1) JP2023527926A (cg-RX-API-DMAC10.html)
KR (1) KR20230038180A (cg-RX-API-DMAC10.html)
CN (1) CN116322767A (cg-RX-API-DMAC10.html)
AU (1) AU2021286202A1 (cg-RX-API-DMAC10.html)
BR (1) BR112022024745A2 (cg-RX-API-DMAC10.html)
CA (1) CA3185020A1 (cg-RX-API-DMAC10.html)
IL (1) IL298757A (cg-RX-API-DMAC10.html)
MX (1) MX2022015229A (cg-RX-API-DMAC10.html)
TW (3) TW202210102A (cg-RX-API-DMAC10.html)
WO (3) WO2021245233A1 (cg-RX-API-DMAC10.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202342057A (zh) * 2022-02-07 2023-11-01 美商健生生物科技公司 用於減少用ｅｇｆｒ／ｍｅｔ雙特異性抗體治療之患者的輸注相關反應之方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ243706A (en) 1991-07-25 1994-08-26 Idec Pharma Corp Recombinant monkey antibodies, pharmaceutical compositions
US8187593B2 (en) * 2002-08-14 2012-05-29 Macrogenics, Inc. FcγRIIB specific antibodies and methods of use thereof
MX2012004406A (es) * 2009-10-21 2012-05-08 Immunogen Inc Nuevo regimen de dosificacion y metodo de tratamiento.
GB201013989D0 (en) 2010-08-20 2010-10-06 Univ Southampton Biological materials and methods of using the same
GB2526139A (en) 2014-05-15 2015-11-18 Biolnvent Internat Ab Medicaments, uses and methods
CN108602889A (zh) * 2015-12-22 2018-09-28 瑞泽恩制药公司 医治急性成淋巴细胞性白血病的双特异性抗cd20/抗cd3抗体
WO2019081983A1 (en) * 2017-10-25 2019-05-02 Novartis Ag CD32B TARGETING ANTIBODIES AND METHODS OF USE
JP7800852B2 (ja) 2018-01-10 2026-01-16 バイオインヴェント インターナショナル アーベー 抗体の新規組み合わせおよびその使用
EA202190102A1 (ru) 2018-08-16 2021-07-29 Генмаб А/С Коньюгаты антител к тканевым факторам с лекарственным средством и их применение в лечении рака
ES3009025T3 (en) 2018-08-31 2025-03-25 Regeneron Pharma Dosing strategy that mitigates cytokine release syndrome for cd3/cd20 bispecific antibodies

Also Published As

Publication number Publication date
JP2023527926A (ja) 2023-06-30
IL298757A (en) 2023-02-01
EP4161573A1 (en) 2023-04-12
BR112022024745A2 (pt) 2023-03-07
KR20230038180A (ko) 2023-03-17
AU2021286202A1 (en) 2023-01-19
TW202210104A (zh) 2022-03-16
CA3185020A1 (en) 2021-12-09
WO2021245238A9 (en) 2023-02-02
CN116322767A (zh) 2023-06-23
TW202210102A (zh) 2022-03-16
WO2021245238A1 (en) 2021-12-09
TW202210103A (zh) 2022-03-16
EP4161574A1 (en) 2023-04-12
WO2021245237A1 (en) 2021-12-09
US20240301070A1 (en) 2024-09-12
WO2021245233A1 (en) 2021-12-09
US20230322933A1 (en) 2023-10-12

Similar Documents

Publication Publication Date Title
Wallach et al. Advances in the treatment of neuromyelitis optica spectrum disorder
Wei et al. A phase 1b study evaluating the safety and efficacy of venetoclax in combination with azacitidine in treatment-naïve patients with higher-risk myelodysplastic syndrome
DiPippo et al. Tolerability of isavuconazole after posaconazole toxicity in leukaemia patients
Schlesinger Canakinumab in gout
EA201691347A3 (ru) Терапия глатирамером ацетатом с низкой кратностью
Riedl et al. Prospective, systematically recorded mycophenolate safety data in Graves’ orbitopathy
Sebastian et al. Current pharmacologic options and emerging therapeutic approaches for the management of ulcerative colitis: a narrative review
Van Hiele l-5-Hydroxytryptophan in depression: the first substitution therapy in psychiatry? The treatment of 99 out-patients with ‘therapy-resistant’depressions
BR112022009283A2 (pt) Métodos de tratamento do câncer do pulmão de células pequenas com formulações de lurbinectedina
BR112022013264A2 (pt) Combinação de formas de dosagem oral sólida de decitabina e cedazuridina
BR112021022503A2 (pt) Métodos de administração de anticorpo anti-cd38 para tratar mieloma múltiplo
BR112022018647A2 (pt) Métodos para dose de iniciação de tratamentos com aripipazol
Mancuso et al. NXT007 prophylaxis in people with hemophilia A with or without FVIII inhibitors: A global Phase I/II multiple-ascending-dose study
HRP20150889T1 (hr) Postupci za lijeäśenje adhezivnog kapsulitisa
Konopleva et al. SL-401, a targeted therapy directed to the interleukin-3 receptor present on leukemia blasts and cancer stem cells, is active as a single agent in patients with advanced AML
BR112022024745A2 (pt) Melhora de tolerabilidade de anticorpo associada a administração intravenosa
Musick et al. P276 Long-term safety, and efficacy of subcutaneous Efgartigimod PH20 in patients with generalized myasthenia gravis: interim results of ADAPT-SC+
Bonkovsky et al. S1170 Efficacy and Safety of Givosiran in Patients With Acute Hepatic Porphyria: 24-Month Interim Analysis of the Phase 3 ENVISION Randomized Clinical Trial
PH12022551256A1 (en) Method for administration of ursodeoxycholic acid
Yurttas et al. POS1381 biologic treatment of adult-onset Still's disease: A single center experience
Denton et al. POS1278 SAFETY AND PHARMACOKINETICS OF IGPRO20 (SUBCUTANEOUS IMMUNOGLOBULIN) AND IGPRO10 (INTRAVENOUS IMMUNOGLOBULIN) IN ADULTS WITH SYSTEMIC SCLEROSIS (SSC)–RESULTS FROM A PHASE 2 TRIAL
Cassiman et al. S1171 EXPLORE Part B: A Prospective, International, Long-Term Natural History Study of Patients With Acute Hepatic Porphyria With Recurrent Symptoms
Sanchorawala et al. Modified high-dose melphalan and autologous stem cell transplantation (mHDM/SCT) in the treatment of AL amyloidosis (AL) and/or high-risk myeloma (hM): analysis of SWOG trial S0115
Boilini et al. Is Ketamine the New Wonder Drug for Treating Suicide?
Reifenschweiler Pethidine abuse